Venezuela issues draft guideline for bioterapéuticos similares

Home/Guidelines | Posted 06/12/2013 post-comment0 Post your comment

The Venezuelan Instituto Nacional de Higiene ‘Rafael Rangel’ (INHRR National ‘Rafael Rangel’ Institute of Hygiene) via its National Monitoring Biological Products Division has released a new draft guideline for bioterapéuticos similares (similar biotherapeutics) in Venezuela.

Venezuela INHRR logo V13L06

Regulations for the registration of biological products were implemented in Venezuela in 2000, making them formally distinct from those for small molecule products.

Bioterapéuticos similares are defined in Venezuela as biotechnology-derived drugs that are similar in terms of quality, safety and efficacy to their reference biotherapeutic products.

Until now regulations in Venezuela have considered that all biological products are new and there has been no distinct regulatory pathway for bioterapéuticos similares.

The proposed draft guideline aims to facilitate the registration of bioterapéuticos similares in Venezuela through an abbreviated pathway.

Guideline for registration and pharmacovigilance of bioterapéuticos similares
Date: 12 June 2012

The proposed draft guideline covers well-defined and characterized biotechnology products, i.e. drugs whose active ingredient are therapeutic proteins derived from recombinant DNA or monoclonal antibodies. Vaccines, plasma products and other biological products whose preparation does not involve genetic manipulation are excluded from the scope of the guideline.

The proposed draft guideline does not allow for extrapolation of indications, with comparability studies for each separate indication required.

The draft guideline has been released for public consultation and feedback should be sent to the INHRR via and Comments on the draft guideline will be accepted until 13 December 2013.

Editor’s comment
It should be noted that bioterapéuticos similares approved in Venezuela might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the EU. EMA regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product. 

If you would like to receive a copy* of the proposed draft guideline, please email us.

*For profit organizations subjected to a fee

Related articles

Colombia issues draft decree for registration of biosimilars

Egypt issues draft guidelines for biosimilars

India releases draft ‘similar biologic’ guidelines

FDA finally issues draft biosimilar guidance

EU guidelines for biosimilars

Global guidelines for biosimilars


1.  GaBI Online - Generics and Biosimilars Initiative. Regulation of similar biotherapeutic products in Latin America []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Dec 6]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: Instituto Nacional de Higiene ‘Rafael Rangel’

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010